T. Shevtsova, V. Nadtocheeva, S. Nimiritskaya, L. Akulkina, N. Bulanov, P. Novikov
{"title":"利妥昔单抗治疗系统性硬化症","authors":"T. Shevtsova, V. Nadtocheeva, S. Nimiritskaya, L. Akulkina, N. Bulanov, P. Novikov","doi":"10.32756/0869-5490-2021-2-31-35","DOIUrl":null,"url":null,"abstract":"To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"13 21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rituximab in systemic sclerosis\",\"authors\":\"T. Shevtsova, V. Nadtocheeva, S. Nimiritskaya, L. Akulkina, N. Bulanov, P. Novikov\",\"doi\":\"10.32756/0869-5490-2021-2-31-35\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"13 21 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2021-2-31-35\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2021-2-31-35","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
